Antisense Therapeutics Scientist Out To Pull More Big Deals Aiming for more major licensing deals like the one his company recently secured with top 20 global pharmaceutical company, Teva, is front of mind for rising Australian biotechnology star, Antisense Therapeutics Ltd (ASX code: ANP)Research Director Dr Christopher Wraight when he meets with leading industry figures in the US in May.
Source: www.medicalnewstoday.comUCSF Program Achieves Over 56% Reduction In Medication Administration Error A demonstration program at UCSF reported a 56.8% reduction in medication administration errors - increasing the administration accuracy rate at participating hospitals to 93%. These gains were achieved through adherence to a set of six "best practice" procedures for medication administration identified by CalNOC (the California Nursing Outcomes Coalition).
Source: www.medicalnewstoday.comImplantable Device Designed For Type-2 Diabetes Patients Who Are Overweight And Do Not Respond To Current Oral Anti-Diabetic Treatments New York-Presbyterian Hospital/Weill Cornell Medical Center is recruiting patients for a national clinical research study of an investigational implantable device designed to help those with type-2 diabetes who are overweight and do not respond to current oral anti-diabetic treatments.
Source: www.medicalnewstoday.comSafety, Efficacy In On-And-Off-label Use Demonstrated In Largest Ever Analysis Of Drug-Eluting Stents Data The Cardiovascular Research Foundation (CRF) will present results of the largest meta-analysis to date comparing mortality rates for drug-eluting stents (DES) versus bare metal stents (BMS) at the Drug-Eluting Stent Revolution VII meeting in Chicago.The analysis - which includes approximately 180,000 patients from 52 studies - was performed by a team of researchers led by Ajay J.
Source: www.medicalnewstoday.comSocial Security Disability Insurance Recipients Need Better Understanding Of Pros And Cons Of New Debit Card, Allsup Says (USA) Starting next month Social Security Disability Insurance recipients in some states will have the option of receiving their benefit payments electronically on a debit card, rather than via a paper check.
Source: www.medicalnewstoday.comReflect Scientific, Inc. Receives U.S. Patent For Catalytic Inspection Method Reflect Scientific, Inc. (OTCBB: RSCF) announces that the Company has been issued another patent from the United States Patent Office. The patent discloses a unique method for inspecting an object having a planar face with surface variations. Management believes that the intellectual property contained within the issued patent will enhance Miralogix's inspection instrumentation, thus offering more features and value to our customers.
Source: www.medicalnewstoday.com
# posted by Network @ 10:01 AM
